谭建新 于玲莉 王冲
摘 要 目前,我国嵌合抗原受体T细胞(chimeric antigen receptor T cell, CAR-T细胞)治疗产品研发如火如荼,其中个别品种即将进入报产上市阶段。本文结合国内产业的实际情况和现有的药品监管经验,就今后在CAR-T细胞治疗产品生产过程中实施GMP方面可能存在的共性问题及监管要求进行思考与分析,希望能为业界提供参考。
关键词 嵌合抗原受体T细胞 细胞治疗产品 药品GMP
中图分类号:R951 文献标志码:C 文章编号:1006-1533(2020)15-0064-07
An introduction to chimeric antigen receptor T cell therapy products and their current status of GMP implementation
TAN Jianxin*, YU Lingli, WANG Chong
(Shanghai Center for Drug Evaluation and Inspection, Shanghai 201203, China)
ABSTRACT In recent years, China has become one of the most active players in chimeric antigen receptor T cell (CAR-T cell) therapy development. With the rapid advancement of CAR-T cell clinical trials, some products are going to commercial manufacturing stage. In this article, we would like to discuss and analyze the common problems and regulatory requirements that may exist in the manufacturing processes based on the current situation of domestic CAR-T cell industrial construction and existing regulatory experiences so as to provide reference for this industry.
KEY WORDS chimeric antigen receptor T cell; cellular therapy products; GMP for drugs
随着诺华公司的Kymriah(tisagenlecleucel)和凯特公司的Yescarta(axicabtagene ciloleucel)相继获得美国FDA和欧盟委员会的上市许可,嵌合抗原受体T细胞(chimeric antigen receptor T cell, CAR-T细胞)治疗产品研发已成为近年来抗肿瘤药物研究领域中的热点之一。
随着技术成熟和资本涌入,目前我国CAR-T细胞治疗产品研发已进入到一个快速发展的阶段。截至2020年2月20日,国家药品审评中心(Center for Drug Evaluation, CDE)共受理了来自26个申请人/联合申请人的40项CAR-T细胞治疗产品的临床研究申请,除了国内企业独立研发的品种外,还有通过合资或进口方式申请的已获美国FDA批准的2种品种,40项申请中已有21项获准开展临床试验(表1)。所有申请的CAR-T细胞治疗产品均为自体回输制剂,适应证以治疗B细胞抗原CD19或B细胞成熟抗原(B cell maturation antigen, BCMA)阳性的血液系统肿瘤为主(表2),所用CAR-T细胞分子载体工艺则包括慢病毒、反转录病毒感染表達和质粒直接转染表达等。与传统药物研发需要经历大规模、长时间的临床试验不同,CAR-T细胞治疗产品的临床研究设计往往更为灵活,为期较短。随着临床试验项目的快速推进,国内个别品种即将进入报产上市阶段。……